PSTX poseida.com Company Net Income

Corporate emblem and logo of poseida.com (PSTX)

Poseida Therapeutics (PSTX) relies on competent management and a transparent alliance with Roche to minimize risks. This chart in the GURU.Markets terminal illustrates the company's revenue surplus, where the value has stabilized at -0.06. The brand's impeccable status in oncology guarantees market confidence, while the platform's versatility ensures high scalability of products for combating various diseases.

PSTX Poseida Therapeutics, Inc.: Net Income in the range 07/04/2022 - 01/18/2025

Financial and market metric breakdowns for Poseida Therapeutics, Inc. (PSTX)

- share price and consensus valuation forecast:
Price Chart Poseida Corp|PSTX - Price Target Chart
- market capitalization data:
Market Value Poseida Corp|PSTX - Enterprise Value
- balance sheet equity data:
Book Value of One Share Poseida Therapeutics|PSTX - Company Net Assets|Market-to-Book Ratio poseida.com|PSTX - Cumulative Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Poseida Therapeutics|PSTX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Poseida Therapeutics Inc|PSTX - Company Aggregate Debts|Debts to Book Value Poseida Corp|PSTX - Company Long-Term Debt|Company Short-Term Debt Poseida Therapeutics|Quick Liquidity poseida.com
- business earnings and investment ratios data:
PSTX - Net Income
Fundamental valuation:PSTX Poseida Corp
Manufactured products of Poseida

This indicator determines the issuer's investment stability by measuring the gap between actual cash flows and market capitalization to identify undervalued assets. By analyzing the quarterly earnings of Poseida Therapeutics (PSTX), an investor can gauge the monetization efficiency of CAR-T therapy, where high R&D costs and the implementation of the non-viral piggyBac system directly impact final profitability and the long-term potential of Poseida Therapeutics.

Main competitors

LEGN (Legend Biotech Corp.) - Company Net Income|Company Net Income Sana Biotechnology|Company Net Income autolus.com AUTL|Net Profit ALLO|Selecta Biosciences (RNAC) - Annual Net Income|Cellectis - Net Income|Caribou Biosciences, Inc (CRBU) - Company Net Income|TIL: Net Income|Final Profit GNTA (Genenta Science S.p.A.)|IPSC: Net Profit|Net Income Jasper Therapeutics, Inc.|SNTI (Senti Bio) - Net Profit|Company Net Income Adaptimmune Therapeutics PLC ADAP|Company Net Income CERo Therapeutics (CERO)|Company Net Income TCRT (alaunos.com)|Company Net Income Achilles Therapeutics plc ACHL|CARGO Therapeutics Inc. - Company Net Income|TSVT: Net Income|Final Profit GRCL (Gracell)